期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

多发性硬化症的药物治疗进展 被引量：7

Emerging therapies for multiple sclerosis
原文传递
导出
摘要 多发性硬化症(MS)是一种复杂、致残的慢性神经系统疾病,全球MS患者超过210万。从1993年首个专门治疗RRMS药物获得美国FDA批准上市以来,全球已陆续批准12个疾病修饰药物(DMAs)上市。医疗专业人员需判断药物收益风险比,以确定每个患者的最佳治疗方案。本文综述了已上市的多发性硬化症的治疗药物,为临床用药提供参考。 Multiple sclerosis （MS） is a complex, chronic, and often disabling neurological disease, and MS affects more than 2.1 million people worldwide. Since the first MS drug was approved by the U. S. Food and Drug Administration （FDA） specially to treat RRMS in 1993, 12 approved DMAs emerged from years in the world. Health care professionals should evaluate cost-effectiveness of the therapies to determine the treatment option that best fits the needs and preferences of individual patients.
作者 程睿 徐飞虎 周胜军 孙汉栋
机构地区 杭州九源基因工程有限公司
出处 《中国新药杂志》 CAS CSCD 北大核心 2014年第23期2748-2752,共5页 Chinese Journal of New Drugs
关键词 多发性硬化 干扰素Β 醋酸格拉替雷 那他珠单抗 芬戈莫德 富马酸二甲酯 multiple sclerosis IFNβ glatiramer acetate natalizumab fingolimod tecfidera
分类号 R971 [医药卫生—药品]
  • 相关文献

参考文献23

  • 1BANDARI DS, STERN AMAN D, CHAN T, et 01. Evaluating risks, costs, and benefits of new and emerging therapies to optimize outcomes in multiple sclerosis [J]. J Manag Care Pharm, 2012,18(9):1 -17.
  • 2LUBLIN FD, REINGOLD SC. Defining the clinical course of multiple sclerosis: results of an international survey. National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis [J]. Neurology, 1996, 46(4) :907 -911.
  • 3MILLER DH, CHARD DT, CICCARELLI O. Clinically isolated syndromes [J] . Lancet Neurol, 2012,11 (2) : 157 - 169.
  • 4COMABELLA M, KHOURY SJ. Immunopathogenesis of multiple sclerosis [J] . Clin Immunol, 2012,142 (1 ) :2 - 8.
  • 5BO L, GEURTS JJ, MORK SJ, et al. Grey matter pathology in multiple sclerosis [J]. Acta Neurol Scand Suppl , 2006, 183: 48 - 50.
  • 6SPERANDEO K, NOGRADY L, MOREO K, et al. Managed approaches to multiple sclerosis in special populations [J]. J Manag Care Pharm, 2011,17(9 Suppl C) :SI - S19.
  • 7KANTARCI OH, PIRKO I, RODRIGUEZ M. Novel immunomodulatory approaches for the management of multiple sclerosis [J]. Clin Pharmacol Ther , 2014,95 (1) :32 - 44.
  • 8PETER C, BERND K, DOUGLAS A, et al. Phase 3 study of PEGylated interferon beta-l a for relapsing multiple sclerosis: patient baseline characteristics [J]. Neurol, 2012, 78 ( Meeting Abstracts 1) : 133.
  • 9PATY DWl, LI DK. Interferon beta-lb is effective in relapsingremitting multiple sclerosis. II. MRI analysis results of a multicenter, randomized, double-blind, placebo-controlled trial. UBC MS/MRI Study Group and the IFNB Multiple Sclerosis Study Group[J].Neurology, 1993,43(4) :662 -667.
  • 10ANTONELLI G, SIMEONI E, BAGNATO F, et al. Further study on the specificity and incidence of neutralizing antibodies to interferon (IFN) in relapsing remitting multiple sclerosis patients treated with IFN beta-l a or IFN beta-l b [J]. J Neurol Sci, 1999,168(2) :131 -136.

二级参考文献46

  • 1McDonald WI,Compston A,Edan G,et al.Recommended diagnostic criteria for multiple sclerosis:guidelines from the international panel on the diagnosis of multiple sclerosis[J].Ann Nurol,2001,50(1):121-127.
  • 2Pinhas IS,Achiron A,Gilad R,et al.Peripheral neuropathy in multiple sclerosis:a clinical and electrophysiologic study[J].Acta Neurol Scand,1995,91:234-238.
  • 3Simon JH.Brain and spinal cord atrophy in multiple sclerosis[J].Neuroimaging Clin N Am,2000,10(4):753-770.
  • 4Victor M,Ropper AH.Adams[M]//Victor's principles of neurology.7 th ed.New York:Mc Graw-Hill Companies,Inc,2001:954-982.
  • 5TOWLE MJ, SALVATO KA,BUDROW J ,et al. In vitro and invivo anticancer activities of synthetic macrocyclic ketone ana-logues of halichondrin B [ J ]. Cancer Res,2001,61 (3 ) : 1013 -1021.
  • 6ZHENG W,SELETSKY BM,PALME MH,ef al. Macrocyclic ke-tone analogues of halichondrin B [ J ]. Bioorg Med Chem Lett,2004,14(22) :5551 -5554.
  • 7DELBUFALO D,CIUFFREDA L’TRISCIUOGLIO D,et al. Anti-angiogenic potential of the mammalian target of rapamycin inhibi-tor temsirolimus[ J ]. Cancer Res ,2006 ,66 (11) :5549 - 5554.
  • 8SUM PE,LEE VJ,TESTA RT,et al. Glycylcyclines 1 a new gen-eration of potent antibacterial agents through modification of 9-aminotetracyclines[ J] ? J Med Chem, 1994,37 ( 1 ) : 184 - 188.
  • 9VENKATRAMAN S,BOGEN SL,ARASAPPAN A,et al. Discov-ery of ( 1 , 5 5) -N- [ 3 -amino-1 - ( cyclobutylmethyl )-2,3 -dioxo-propyl ]-3-[2(5)-[[[(l,l -dimethylethyl) amino ] carbonyl ] a-mino] -3,3-dimethyl-1 -oxobutyl ] -6,6 -dimethyl-3 -azabicyclo [ 3.1.0] hexan-2 ( S) -carboxamide ( SCH 503034 ),a selective,po-tent ,orally bioavailable hepatitis C virus NS3 protease inhibitor:Apotential therapeutic agent for the treatment of hepatitis C infec-tion[J], J Med Chem,2006,49(20) :6074 -6086.
  • 10NJOROGE FG,CHEN KX’SHIH NY,et al. Challenges in mod-ern drug discovery : a case study of boceprevir, an HCV proteaseinhibitor or the treatment of hepatitis C virus infection [ J]. AccChem ^,2008,41(1) :50 -59.

共引文献7

同被引文献67

引证文献7

二级引证文献5

中国新药杂志
2014年 第23期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部